Opinion
Video
Author(s):
Corey Cutler, MD, MPH, discusses the role of prognostic markers in graft-vs-host disease and how they can potentially inform treatment selection.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Rapcabtagene Autoleucel May Be Safe and Efficacious in R/R DLBCL
FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL
NKT2152 Ushers in a New Era of HIF-2α Inhibition in Pretreated Advanced ccRCC
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
The OncFive: Top Oncology Articles for the Week of 1/19
FDA Approves Treosulfan for alloHCT Conditioning in AML and MDS
OS With Chemotherapy Is Linked With Baseline Geriatric, QOL Factors in Metastatic Pancreatic Cancer
Bezuclastinib Plus Sunitinib Elicits Preliminary Activity, Is Safe in Pretreated GIST
Post-Chemotherapy ctDNA Status May Support Organ Preservation Decisions in Rectal Cancer
Adagrasib/Cetuximab Maintains Efficacy in KRAS G12C–Mutated Advanced mCRC
REZILIENT1 Study of Zipalertinib in Pretreated EGFR-Mutant NSCLC Meets ORR Primary End Point
Azenosertib Monotherapy Appears Safe and Effective in Ovarian Cancer
Tissue-Based NGS May Help Determine Relevant Gene Copy Number Gain Cutpoint for HER2/KRAS/MET in NSCLC
Routine Intraoperative Frozen Section Represents a "Very Costly" Soft Tissue Sarcoma Procedure